OFFICE LEASE 601 GATEWAY BOULEVARD GATEWAY CENTER, LLC, a California limited liability company as Landlord, and D-NOVO THERAPEUTICS, INC. a Delaware corporation as Tenant.Office Lease • February 10th, 2006 • Novacea Inc • California
This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between GATEWAY CENTER, LLC, a California limited liability company (“Landlord”), and D-NOVO THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SUPPLY AGREEMENTSupply Agreement • February 10th, 2006 • Novacea Inc • New Jersey
THIS SUPPLY AGREEMENT is entered into this 27th day of December, 2001 by and between PLANTEX USA, Inc., a corporation organized under the laws of the State of New Jersey with offices at 482 Hudson Terrace, Englewood Cliffs, New Jersey 07632 (“PLANTEX”) and D-NOVO Therapeutics, Inc., a corporation organized under the laws of the State of Delaware with offices at 28202 Cabot Road, Suite 200, Laguna Niguel, California 92677 (“D-NOVO”).
LICENSE AGREEMENTLicense Agreement • February 10th, 2006 • Novacea Inc • Pennsylvania
This License Agreement (the “Agreement”) is made and entered into as of the 1st day of July, 2002 (the “Effective Date”), by and between the UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, a non-profit corporation, organized and existing under the laws of the Commonwealth of Pennsylvania, having its principal office at 4200 Fifth Avenue, Pittsburgh, Pennsylvania 15260 (“UNIVERSITY”) and NOVACEA, INC., a Delaware corporation having its primary place of business at 601 Gateway Boulevard, Suite 450, South San Francisco, California 94080 (“LICENSEE”).
EXCLUSIVE LICENSE AGREEMENT BETWEEN OHSU AND D-NOVO THERAPEUTICS, INC.Exclusive License Agreement • February 10th, 2006 • Novacea Inc • Oregon
This Agreement is made and entered into between the Oregon Health & Science University (hereinafter OHSU) having offices at 3181 S. W. Sam Jackson Park Road, Portland, Oregon 97201-3098, and D-Novo Therapeutics, Inc. (hereinafter Licensee), a California corporation having offices at 28202 Cabot Road, Suite 200, Laguna Niguel, California 92677 on this 27th day of June, 2001 (“Effective Date”).
PATENT AND KNOW-HOW LICENSE AGREEMENT Between PIERRE FABRE MEDICAMENT S.A. and NOVACEA, Inc. Dated July 19, 2005Patent and Know-How License Agreement • February 10th, 2006 • Novacea Inc • New York
THIS PATENT AND KNOW-HOW LICENSE AGREEMENT (the “Agreement”) is executed on July 19, 2005 (the “Effective Date”) by and between PIERRE FABRE MEDICAMENT S.A., a corporation organized under the laws of France with headquarters at 45, place Abel-Gance, 921000 BOULOGNE, FRANCE (“PIERRE FABRE”) and NOVACEA, INC., a Delaware corporation with a principal place of business at 601 Gateway Boulevard, Suite 800, SOUTH SAN FRANCISCO, CALIFORNIA 94080, U.S.A. (“NOVACEA”).
SUPPLY AGREEMENT between PIERRE FABRE MEDICAMENT S.A. and NOVACEA, Inc. Dated July 19, 2005Supply Agreement • February 10th, 2006 • Novacea Inc • York
THIS SUPPLY AGREEMENT (the “Agreement”) is executed on July 19, 2005 (the “Effective Date”) by and between PIERRE FABRE MEDICAMENT S.A., a corporation organized under the laws of France with headquarters at 45, place Abel-Gance, 92100 BOULOGNE, FRANCE (“PIERRE FABRE”), and NOVACEA, INC. a Delaware corporation with a principal place of business at 601 Gateway Boulevard, Suite 800, SOUTH SAN FRANCISCO, CALIFORNIA 94080, U.S.A. (“NOVACEA”).
LICENSE AGREEMENTLicense Agreement • February 10th, 2006 • Novacea Inc • England
THIS LICENSE AGREEMENT (the “Agreement”) is made effective as of the 3rd day of December, 2003 (the “Effective Date”) by and between NOVACEA, INC., a Delaware corporation having its principal place of business at 601 Gateway Boulevard, Suite 801, South San Francisco, CA 94080 (“Novacea”), and KuDOS PHARMACEUTICALS LIMITED a United Kingdom corporation having its principal place of business at 327 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4, oWG, UK (“KuDOS”). KuDOS and Novacea are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED FIRST AMENDMENT TO LEASELease • February 10th, 2006 • Novacea Inc
This Amended and Restated First Amendment to Lease (this “Restated Amendment”) is entered into effective as of the 1st day of September, 2004, by and between GATEWAY CENTER LLC, a Delaware limited liability company (“Landlord”) and NOVACEA, INC., a Delaware corporation (“Tenant”).
AGREEMENTAgreement • February 10th, 2006 • Novacea Inc • New Jersey
This Agreement with Novacea Inc. (hereinafter referred to as “Sponsor”) with an address of 601 Gateway Boulevard, Suite 450, South San Francisco, California 94080, is the sponsor or sponsor-investigator, as those terms are defined in Title 21 of the Code of Federal Regulations, CFR 312.3, of a study (the “Study”) entitled:
AGREEMENTAgreement • February 10th, 2006 • Novacea Inc • New Jersey
This Grant-in-Aid Agreement with Novacea Inc. (hereinafter referred to as “Sponsor”) with an address of 601 Gateway Boulevard, Suite 450, South San Francisco, California 94080, is the sponsor or sponsor-investigator, as those terms are defined in Title 21 of the Code of Federal Regulations, CFR 312.3, of a study (the “Study”) entitled:
FIRST AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • February 10th, 2006 • Novacea Inc • New Jersey
THIS FIRST AMENDMENT TO SUPPLY AGREEMENT (the “Amendment”) is dated as of January 24, 2006, by and between Novacea, Inc., a Delaware corporation previously known as D-NOVO Therapeutics, Inc. (“Novacea”) and Plantex USA, Inc., a Delaware corporation (“Plantex”).
SECOND AMENDMENT TO LEASETo Lease • February 10th, 2006 • Novacea Inc
This Second Amendment to Lease (this “Amendment”) is entered into effective as of the 1st day of June, 2005, by and between GATEWAY CENTER LLC, a Delaware limited liability company (“Landlord”) and NOVACEA, INC., a Delaware corporation (“Tenant”).
NOVACEA, INC. December 21, 2005Investor Rights Agreement • February 10th, 2006 • Novacea Inc • California
This 2005 Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of December 21, 2005 among Novacea, Inc, a Delaware corporation (the “Company”), the stockholders listed on Exhibit A hereto (individually an “Investor” and collectively the “Investors”), Oregon Health & Science University (“OHSU”), and University of Pittsburgh of the Commonwealth System of Higher Education (“Pitt”).
TRADEMARK LICENSE AGREEMENT between PIERRE FABRE MEDICAMENT S.A. and NOVACEA, Inc. Dated July 19, 2005Trademark License Agreement • February 10th, 2006 • Novacea Inc • New York
THIS TRADEMARK LICENSE AGREEMENT (the “Agreement”) is executed on July 19, 2005 (the “Effective Date”) by and between PIERRE FABRE MEDICAMENT S.A., a corporation organized under the laws of France with headquarters at 45, place Abel-Gance, 92100 BOULOGNE, FRANCE (“PIERRE FABRE”), and NOVACEA, INC., a Delaware corporation with a principal place of business at 601 Gateway Boulevard, Suite 800, SOUTH SAN FRANCISCO, California 94080, U.S.A. (“NOVACEA”).
